Recent advancements in obesity pharmacotherapy have seen the approval of novel agents, like glucagon-like peptide-1 receptor agonist and dual agonists, offering unprecedented efficacy for obesity management. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.